Iranian Journal of Radiology

Published by: Kowsar

Hepatocellular Carcinoma is an Emerging Issue Now in Iran

Seyed Moayed Alavian 1 , *
Author Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
Article information
  • Iranian Journal of Radiology: October 2017, 14 (4); e64371
  • Published Online: October 31, 2017
  • Article Type: Editorial
  • Received: December 20, 2017
  • Accepted: December 24, 2017
  • DOI: 10.5812/iranjradiol.64371

To Cite: Alavian S M. Hepatocellular Carcinoma is an Emerging Issue Now in Iran, Iran J Radiol. 2017 ;14(4):e64371. doi: 10.5812/iranjradiol.64371.

Copyright: Copyright © 2017, Iranian Journal of Radiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Hepatitis B and HCC
3. Hepatitis C and HCC
4. Obesity, Diabetes and HCC
5. In Conclusion
  • 1. Ghanaati H, Alavian SM, Jafarian A, Ebrahimi Daryani N, Nassiri-Toosi M, Jalali AH, et al. Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence. Iran J Radiol. 2012;9(4):167-77. doi: 10.5812/iranjradiol.8242. [PubMed: 23407596].
  • 2. Xu Y, Xiao A, Yang J, Zhang Z, Zhang G. Assessment of lipiodol deposition and residual cancer for hepatocellular carcinoma after transcatheter arterial chemoembolization via iodine based material decomposition images with spectral computed tomography imaging, a preliminary Study. Iran J Radiol. 2015;12(4):26009. doi: 10.5812/iranjradiol.26009. [PubMed: 26715981].
  • 3. Jalli R, Jafari SH, Sefidbakht S, Kazemi K. Comparison of the accuracy of DWI and ultrasonography in screening hepatocellular carcinoma in patients with chronic liver disease. Iran J Radiol. 2015;12(1):12708. doi: 10.5812/iranjradiol.12708. [PubMed: 25785178].
  • 4. Hemmati H, Karimian M, Moradi H, Farid Marandi K, Haghdoost A. Endovascular treatment of a huge hepatic artery aneurysm by coil embolization method, a case report. Iran J Radiol. 2015;12(3):5200. doi: 10.5812/iranjradiol.5200. [PubMed: 26528386].
  • 5. Kim CY, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, et al. Clinical features of hepatitis B and C virus infections, with high alpha fetoprotein levels but not hepatocellular carcinoma. Medicine (Baltimore). 2017;96(2):5844. doi: 10.1097/MD.0000000000005844. [PubMed: 28079817].
  • 6. Yang B, You X, Yuan ML, Qin TQ, Duan LJ, He J, et al. Transarterial ethanol ablation combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Hepat Mon. 2016;16(8):37584. doi: 10.5812/hepatmon.37584. [PubMed: 27799963].
  • 7. Alavian SM, Haghbin H. Relative importance of hepatitis B and C viruses in hepatocellular carcinoma in EMRO countries and the middle east, a systematic review. Hepat Mon. 2016;16(3):35106. doi: 10.5812/hepatmon.35106. [PubMed: 27226803].
  • 8. Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian expanded program on immunization (EPI), a systematic review and meta analysis study. Hepat Mon. 2015;15(5):23618. doi: 10.5812/hepatmon.15(04)2015.23618. [PubMed: 26045701].
  • 9. Blum HE. Hepatocellular carcinoma: HCC. Hepat Mon. 2011;11(2):69-70. [PubMed: 22087121].
  • 10. Hajarizadeh B, Mesgarpour B, Nasiri MJ, Alavian SM, Merat S, Poustchi H, et al. Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran. Hepat Mon. 2017;17(8). doi: 10.5812/hepatmon.11715.
  • 11. Stawinska Witoszynska B, Zysnarska M, Krzywinska Wiewiorowska M, Wojtyla Buciorab P, Krzyzaniak A, Wieckowska B. Trends in the incidence rates of chronic hepatitis B in poland in the years 2005-2013. Hepat Mon. 2016;16(8):32692. doi: 10.5812/hepatmon.32692. [PubMed: 27799960].
  • 12. Sosa Jurado F, Hilda Rosas Murrieta N, Guzman Flores B, Perez Zempoaltecalt C, Patricia Sanchez Torres A, Ramirez Rosete L, et al. Prevalence of serologic hepatitis B markers in blood donors from puebla, Mexico, the association of relatively high levels of anti-core antibodies with the detection of surface antigen and genomic DNA. Hepat Mon. 2016;16(6):36942. doi: 10.5812/hepatmon.36942. [PubMed: 27630726].
  • 13. La Fauci V, Riso R, Facciola A, Ceccio C, Lo Giudice D, Calimeri S, et al. Response to anti-HBV vaccine and 10-year follow-up of antibody levels in healthcare workers. Public Health. 2016;139:198-202. doi: 10.1016/j.puhe.2016.08.007. [PubMed: 27600791].
  • 14. Geramizadeh B, Nikeghbalian S, Kazemi K, Shamsaifar A, Bahador A, Salahi H, et al. Hepatocellular carcinoma in explanted livers of patients with genotype d HBV cirrhosis: report of the first experience from Iran. Arch Iran Med. 2013;16(6):348-50. [PubMed: 23725068].
  • 15. Geramizadeh B, Nikeghbalian S, Shamsaifar A, Kazemi K, Malekhosseini SA. Hepatocellular carcinoma in two patients with autoimmune hepatitis, a single center experience and review of the literature. Hepat Mon. 2013;13(4):7957. doi: 10.5812/hepatmon.7957. [PubMed: 23805159].
  • 16. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):45-57. doi: 10.1016/j.jhep.2014.07.027. [PubMed: 25086286].
  • 17. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62. doi: 10.1038/nrgastro.2013.107. [PubMed: 23817321].
  • 18. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-50. doi: 10.1056/NEJM199903113401001. [PubMed: 10072408].
  • 19. El Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):74-83. doi: 10.1053/jhep.2002.36807. [PubMed: 12407579].
  • 20. El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-30. [PubMed: 11088082].
  • 21. Strazzulla A, Iemmolo RMR, Carbone E, Postorino MC, Mazzitelli M, De Santis M, et al. The risk of hepatocellular carcinoma after directly acting antivirals for hepatitis c virus treatment in liver transplanted patients, Is it real?. Hepat Mon. 2016;16(11):41933. doi: 10.5812/hepatmon.41933. [PubMed: 28070200].
  • 22. Montella M, Crispo A, Giudice A. HCC, diet and metabolic factors: Diet and HCC. Hepat Mon. 2011;11(3):159-62. [PubMed: 22087137].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .